{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:20:30Z","timestamp":1789842030974,"version":"4.0.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00277-019-03900-x","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T12:28:47Z","timestamp":1577968127000},"page":"265-276","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma\u2014a long-term follow-up single center experience"],"prefix":"10.1007","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7283-9778","authenticated-orcid":false,"given":"Malte","family":"Roerden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"S\u00f6kler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Kanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Bethge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wichard","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6404-7391","authenticated-orcid":false,"given":"Juliane S.","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,2]]},"reference":[{"issue":"27","key":"3900_CR1","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","volume":"27","author":"A Engert","year":"2009","unstructured":"Engert A, Diehl V, Franklin J, Lohri A, D\u00f6rken B, Ludwig W-D, Koch P, H\u00e4nel M, Pfreundschuh M, Wilhelm M (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin\u2019s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27(27):4548\u20134554","journal-title":"J Clin Oncol"},{"issue":"21","key":"3900_CR2","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2005.09.085","volume":"23","author":"RM Meyer","year":"2005","unstructured":"Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA, Burns BF, Winter JN, Horning SJ, Dar AR (2005) Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin\u2019s lymphoma: National Cancer Institute of Canada clinical trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23(21):4634\u20134642","journal-title":"J Clin Oncol"},{"key":"3900_CR3","doi-asserted-by":"publisher","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","volume":"29","author":"D.A. Eichenauer","year":"2018","unstructured":"Eichenauer D, Aleman B, Andr\u00e9 M, Federico M, Hutchings M, Illidge T, Engert A, Ladetto M (2018) Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):iv19\u2013iv29. https:\/\/doi.org\/10.1093\/annonc\/mdy080","journal-title":"Annals of Oncology"},{"issue":"16","key":"3900_CR4","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1182\/blood-2010-09-288373","volume":"117","author":"J Kuruvilla","year":"2011","unstructured":"Kuruvilla J, Keating A, Crump M (2011) How I treat relapsed and refractory Hodgkin lymphoma. Blood 117(16):4208\u20134217","journal-title":"Blood"},{"issue":"18","key":"3900_CR5","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, De Vos S (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol 30(18):2183\u20132189","journal-title":"J Clin Oncol"},{"issue":"3","key":"3900_CR6","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/annonc\/mdx791","volume":"29","author":"A Herrera","year":"2017","unstructured":"Herrera A, Palmer J, Martin P, Armenian S, Tsai N-C, Kennedy N, Sahebi F, Cao T, Budde L, Mei M (2017) Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol 29(3):724\u2013730","journal-title":"Ann Oncol"},{"issue":"9","key":"3900_CR7","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdf228","volume":"13","author":"P Bierman","year":"2002","unstructured":"Bierman P, Lynch J, Bociek R, Whalen V, Kessinger A, Vose J, Armitage J (2002) The international prognostic factors project score for advanced Hodgkin\u2019s disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol 13(9):1370\u20131377","journal-title":"Ann Oncol"},{"issue":"12","key":"3900_CR8","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.bbmt.2013.09.018","volume":"19","author":"T Hahn","year":"2013","unstructured":"Hahn T, McCarthy PL, Carreras J, Zhang M-J, Lazarus HM, Laport GG, Montoto S, Hari PN (2013) Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma. Biol Blood Marrow Transplant 19(12):1740\u20131744","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"3900_CR9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdi119","volume":"16","author":"A Sureda","year":"2005","unstructured":"Sureda A, Constans M, Iriondo A, Arranz R, Caballero M, Vidal M, Petit J, Lopez A, Lahuerta J, Carreras E (2005) Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 16(4):625\u2013633","journal-title":"Ann Oncol"},{"issue":"9980","key":"3900_CR10","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A (2015) Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385(9980):1853\u20131862","journal-title":"Lancet"},{"issue":"14","key":"3900_CR11","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB (2018) Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 36(14):1428","journal-title":"J Clin Oncol"},{"issue":"4","key":"3900_CR12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 372(4):311\u2013319","journal-title":"N Engl J Med"},{"issue":"6","key":"3900_CR13","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdx072","volume":"28","author":"P Br\u00f6ckelmann","year":"2017","unstructured":"Br\u00f6ckelmann P, M\u00fcller H, Casasnovas O, Hutchings M, von Tresckow B, J\u00fcrgens M, McCall S, Morschhauser F, Fuchs M, Borchmann P (2017) Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann Oncol 28(6):1352\u20131358","journal-title":"Ann Oncol"},{"issue":"11","key":"3900_CR14","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/bmt.2015.177","volume":"50","author":"P Satwani","year":"2015","unstructured":"Satwani P, Ahn KW, Carreras J, Abdel-Azim H, Cairo MS, Cashen A, Chen AI, Cohen JB, Costa LJ, Dandoy C (2015) A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Transplant 50(11):1416\u20131423","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"3900_CR15","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.bmt.1704789","volume":"35","author":"T Hahn","year":"2005","unstructured":"Hahn T, Benekli M, Wong C, Moysich K, Hyland A, Michalek A, Alam A, Baer M, Bambach B, Czuczman M (2005) A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin\u2019s disease. Bone Marrow Transplant 35(6):557\u2013566","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"3900_CR16","first-page":"221","volume":"20","author":"A Josting","year":"2002","unstructured":"Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, Rudolph C, Diehl V, Engert A (2002) New prognostic score based on treatment outcome of patients with relapsed Hodgkin\u2019s lymphoma registered in the database of the German Hodgkin\u2019s lymphoma study group. J Clin Oncol 20(1):221\u2013230","journal-title":"J Clin Oncol"},{"issue":"2","key":"3900_CR17","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1200\/JCO.1995.13.2.396","volume":"13","author":"R Colwill","year":"1995","unstructured":"Colwill R, Crump M, Couture F, Danish R, Stewart AK, Sutton D, Scott JG, Sutcliffe SB, Brandwein JM, Keating A (1995) Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin\u2019s disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 13(2):396\u2013402","journal-title":"J Clin Oncol"},{"issue":"4","key":"3900_CR18","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1200\/JCO.1993.11.4.704","volume":"11","author":"M Crump","year":"1993","unstructured":"Crump M, Smith AM, Brandwein J, Couture F, Sherret H, Sutton D, Scott JG, McCrae J, Murray C, Pantalony D (1993) High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin\u2019s disease: importance of disease status at transplant. J Clin Oncol 11(4):704\u2013711","journal-title":"J Clin Oncol"},{"issue":"2","key":"3900_CR19","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/cncr.21587","volume":"106","author":"J Kuruvilla","year":"2006","unstructured":"Kuruvilla J, Nagy T, Pintilie M, Tsang R, Keating A, Crump M (2006) Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 106(2):353\u2013360","journal-title":"Cancer"},{"issue":"27","key":"3900_CR20","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059","journal-title":"J Clin Oncol"},{"issue":"21","key":"3900_CR21","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, Hoos A, Barrington SF, Armand P (2016) Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128(21):2489\u20132496","journal-title":"Blood"},{"issue":"5","key":"3900_CR22","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood.V79.5.1193.1193","volume":"79","author":"W Brugger","year":"1992","unstructured":"Brugger W, Bross K, Frisch J, Dern P, Weber B, Mertelsmann R, Kanz L (1992) Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. Blood 79(5):1193\u20131200","journal-title":"Blood"},{"issue":"5","key":"3900_CR23","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood.V83.5.1193.1193","volume":"83","author":"DE Reece","year":"1994","unstructured":"Reece DE, Connors JM, Spinelli JJ, Barnett MJ, Fairey RN, Klingemann HG, Nantel SH, O'Reilly S, Shepherd JD, Sutherland HJ et al (1994) Intensive therapy with cyclophosphamide, carmustine, etoposide +\/\u2212 cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 83(5):1193\u20131199","journal-title":"Blood"},{"issue":"8852","key":"3900_CR24","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","volume":"341","author":"D Linch","year":"1993","unstructured":"Linch D, Goldstone A, McMillan A, Chopra R, Hudson GV, Winfield D, Hancock B, Moir D, Milligan D (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial. Lancet 341(8852):1051\u20131054","journal-title":"Lancet"},{"issue":"9323","key":"3900_CR25","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, M\u00fcller P, Kirchner H (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 359(9323):2065\u20132071","journal-title":"Lancet"},{"issue":"4","key":"3900_CR26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ajh.23108","volume":"87","author":"RL Elstrom","year":"2012","unstructured":"Elstrom RL, Martin P, Rua SH, Shore TB, Furman RR, Ruan J, Pearse RN, Coleman M, Mark T, Leonard JP (2012) Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. Am J Hematol 87(4):433\u2013435","journal-title":"Am J Hematol"},{"issue":"10","key":"3900_CR27","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/bmt.2010.294","volume":"46","author":"N Puig","year":"2011","unstructured":"Puig N, Pintilie M, Seshadri T, Al-Farsi K, Franke N, Keating A, Kuruvilla J, Crump M (2011) High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin\u2019s lymphoma. Bone Marrow Transplant 46(10):1339\u20131344","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"3900_CR28","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/bmt.2016.76","volume":"51","author":"A Stamatoullas","year":"2016","unstructured":"Stamatoullas A, Brice P, Gueye M, Mareschal S, Chevallier P, Bouabdallah R, Nguyenquoc S, Francois S, Turlure P, Ceballos P (2016) Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin\u2019s lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC). Bone Marrow Transplant 51(7):928\u2013932","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"3900_CR29","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood.V89.3.801","volume":"89","author":"SJ Horning","year":"1997","unstructured":"Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW, Wong RM, Brown BW, Blume KG (1997) High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 89(3):801\u2013813","journal-title":"Blood"},{"issue":"11","key":"3900_CR30","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1002\/cncr.11414","volume":"97","author":"C Tarella","year":"2003","unstructured":"Tarella C, Cuttica A, Vitolo U, Liberati M, Di Nicola M, Cortelazzo S, Rosato R, Rosanelli C, Di Renzo N, Musso M (2003) High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and\/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer 97(11):2748\u20132759","journal-title":"Cancer"},{"issue":"32","key":"3900_CR31","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1200\/JCO.2017.72.7925","volume":"35","author":"FC Chan","year":"2017","unstructured":"Chan FC, Mottok A, Gerrie AS, Power M, Nijland M, Diepstra A, van den Berg A, Kamper P, d'Amore F, d'Amore AL (2017) Prognostic model to predict post-autologous stem-cell transplantation outcomes in classical Hodgkin lymphoma. J Clin Oncol 35(32):3722\u20133733","journal-title":"J Clin Oncol"},{"issue":"4","key":"3900_CR32","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/annonc\/mdz009","volume":"30","author":"R Garcia-Sanz","year":"2019","unstructured":"Garcia-Sanz R, Sureda A, de la Cruz F, Canales M, Gonzalez A, Pinana J, Rodriguez A, Gutierrez A, Domingo-Domenech E, Sanchez-Gonzalez B (2019) Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO group). Ann Oncol 30(4):612\u2013620","journal-title":"Ann Oncol"},{"issue":"19","key":"3900_CR33","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363(19):1812\u20131821","journal-title":"N Engl J Med"},{"issue":"7","key":"3900_CR34","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1158\/1078-0432.CCR-16-1387","volume":"23","author":"SM Ansell","year":"2017","unstructured":"Ansell SM (2017) Nivolumab in the treatment of Hodgkin lymphoma. Clin Cancer Res 23(7):1623\u20131626","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3900_CR35","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3324\/haematol.2015.132761","volume":"101","author":"S Vardhana","year":"2016","unstructured":"Vardhana S, Younes A (2016) The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints. Haematologica 101(7):794\u2013802","journal-title":"Haematologica"},{"issue":"3","key":"3900_CR36","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","volume":"97","author":"CH Moskowitz","year":"2001","unstructured":"Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, Louie D, Gonzales M, Walits J, Coady-Lyons N (2001) A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 97(3):616\u2013623","journal-title":"Blood"},{"issue":"10","key":"3900_CR37","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood.V77.10.2292.2292","volume":"77","author":"A Lohri","year":"1991","unstructured":"Lohri A, Barnett M, Fairey R, O'Reilly S, Phillips G, Reece D, Voss N, Connors J (1991) Outcome of treatment of first relapse of Hodgkin\u2019s disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood 77(10):2292\u20132298","journal-title":"Blood"},{"issue":"10","key":"3900_CR38","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/sj.bmt.1704483","volume":"33","author":"U Popat","year":"2004","unstructured":"Popat U, Hosing C, Saliba RM, Anderlini P, Van Besien K, Przepiorka D, Khouri IF, Gajewski J, Claxton D, Giralt S (2004) Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin\u2019s lymphoma. Bone Marrow Transplant 33(10):1015\u20131023","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"3900_CR39","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1200\/JCO.1994.12.3.580","volume":"12","author":"MG Pfreundschuh","year":"1994","unstructured":"Pfreundschuh MG, Rueffer U, Larhan B, Schmitz N, Brosteanu O, Hasenclever D, Haas R, Kirchner H, Koch P, Kuse R (1994) Dexa-BEAM inpatients with Hodgkin\u2019s disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin\u2019s Disease Study Group. J Clin Oncol 12(3):580\u2013586","journal-title":"J Clin Oncol"},{"issue":"10","key":"3900_CR40","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/sj.bmt.1701202","volume":"21","author":"V Ribrag","year":"1998","unstructured":"Ribrag V, Nasr F, Bouhris J, Bosq J, Brault P, Girinsky T, Cosset J, Munck J, Corti C, Decaudin D (1998) VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin\u2019s disease. Bone Marrow Transplant 21(10):969\u2013974","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"3900_CR41","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","volume":"132","author":"AS LaCasce","year":"2018","unstructured":"LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell SM, Crosswell HE, Islas-Ohlmayer M, Behler C (2018) Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood 132(1):40\u201348","journal-title":"Blood"},{"issue":"27","key":"3900_CR42","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1200\/jco.2016.66.4466","volume":"34","author":"A Santoro","year":"2016","unstructured":"Santoro A, Mazza R, Pulsoni A, Re A, Bonfichi M, Zilioli VR, Salvi F, Merli F, Anastasia A, Luminari S, Annechini G, Gotti M, Peli A, Liberati AM, Di Renzo N, Castagna L, Giordano L, Carlo-Stella C (2016) Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: final results of a multicenter phase II study. J Clin Oncol 34(27):3293\u20133299. https:\/\/doi.org\/10.1200\/jco.2016.66.4466","journal-title":"J Clin Oncol"},{"issue":"11","key":"3900_CR43","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","volume":"131","author":"AF Herrera","year":"2018","unstructured":"Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K (2018) Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 131(11):1183\u20131194","journal-title":"Blood"},{"issue":"10","key":"3900_CR44","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/annonc\/mdf221","volume":"13","author":"A Josting","year":"2002","unstructured":"Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner H, D\u00f6rken B, Hossfeld D, Diehl V, Engert A (2002) Time-intensified dexamethasone\/cisplatin\/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin\u2019s disease. Ann Oncol 13(10):1628\u20131635","journal-title":"Ann Oncol"},{"issue":"1","key":"3900_CR45","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.0902-4441.2004.00171.x","volume":"72","author":"A Olivieri","year":"2004","unstructured":"Olivieri A, Brunori M, Capelli D, Montanari M, Massidda D, Gini G, Lucesole M, Poloni A, Offidani M, Candela M (2004) Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. Eur J Haematol 72(1):10\u201317","journal-title":"Eur J Haematol"},{"issue":"2","key":"3900_CR46","first-page":"99","volume":"5","author":"J Brandwein","year":"1990","unstructured":"Brandwein J, Callum J, Sutcliffe S, Scott J, Keating A (1990) Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin\u2019s disease. Bone Marrow Transplant 5(2):99\u2013103","journal-title":"Bone Marrow Transplant"},{"issue":"2\u20133","key":"3900_CR47","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/10428199109068113","volume":"5","author":"AK Stewart","year":"1991","unstructured":"Stewart AK, Brandwein JM, Sutcliffe SB, Scott JG, Keating A (1991) Mini-beam as salvage chemotherapy for refractory Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma. Leuk Lymphoma 5(2\u20133):111\u2013115","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"3900_CR48","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1200\/JCO.2001.19.23.4314","volume":"19","author":"A Grn","year":"2001","unstructured":"Grn A, Ambinder RF, Piantadosi S, Abrams RA, Brodsky RA, Vogelsang GB, Zahurak ML, Fuller D, Miller CB, Noga SJ (2001) Long-term results of blood and marrow transplantation for Hodgkin\u2019s lymphoma. J Clin Oncol 19(23):4314\u20134321","journal-title":"J Clin Oncol"},{"issue":"2","key":"3900_CR49","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/JCO.1996.14.2.572","volume":"14","author":"JL Gajewski","year":"1996","unstructured":"Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP, Champlin RE, Herzig RH, Hurd DD, Jagannath S, Klein JP (1996) Bone marrow transplants from HLA-identical siblings in advanced Hodgkin\u2019s disease. J Clin Oncol 14(2):572\u2013578","journal-title":"J Clin Oncol"},{"issue":"8","key":"3900_CR50","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","volume":"31","author":"A Peniket","year":"2003","unstructured":"Peniket A, De Elvira MR, Taghipour G, Cordonnier C, Gluckman E, De Witte T, Santini G, Blaise D, Greinix H, Ferrant A (2003) An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31(8):667\u2013678","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"3900_CR51","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41409-019-0640-z","volume":"55","author":"Mar\u00eda Marta Rivas","year":"2019","unstructured":"Rivas MM, Berro M, Prates MV, Yantorno S, Fiad L, Arbelbide JA, Basquiera AL, Ferini GA, Garc\u00eda JJ, Garc\u00eda PA (2019) Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment. Bone Marrow Transplant. https:\/\/doi.org\/10.1038\/s41409-019-0640-z","journal-title":"Bone Marrow Transplantation"},{"issue":"7","key":"3900_CR52","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/bmt.2017.44","volume":"52","author":"F Covut","year":"2017","unstructured":"Covut F, Pinto R, Cooper BW, Tomlinson B, Metheny L, Malek E, Lazarus HM, de Lima M, Caimi PF (2017) Nivolumab before and after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 52(7):1054\u20131056. https:\/\/doi.org\/10.1038\/bmt.2017.44","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"3900_CR53","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/bmt.2017.69","volume":"52","author":"J El Cheikh","year":"2017","unstructured":"El Cheikh J, Massoud R, Abudalle I, Haffar B, Mahfouz R, Kharfan-Dabaja MA, Jisr T, Mougharbel A, Ibrahim A, Bazarbachi A (2017) Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplant 52(7):1074\u20131077. https:\/\/doi.org\/10.1038\/bmt.2017.69","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"3900_CR54","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","volume":"129","author":"RW Merryman","year":"2017","unstructured":"Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Perales MA, Avigdor A, Halwani AS, Houot R, Marchand T, Dhedin N, Lescaut W, Thiebaut-Bertrand A, Francois S, Stamatoullas-Bastard A, Rohrlich PS, Labussiere Wallet H, Castagna L, Santoro A, Bachanova V, Bresler SC, Srivastava A, Kim H, Pesek E, Chammas M, Reynolds C, Ho VT, Antin JH, Ritz J, Soiffer RJ, Armand P (2017) Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma. Blood 129(10):1380\u20131388. https:\/\/doi.org\/10.1182\/blood-2016-09-738385","journal-title":"Blood"},{"issue":"1","key":"3900_CR55","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","volume":"25","author":"A Ijaz","year":"2019","unstructured":"Ijaz A, Khan AY, Malik SU, Faridi W, Fraz MA, Usman M, Tariq MJ, Durer S, Durer C, Russ A (2019) Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant 25(1):94\u201399","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"3900_CR56","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11899-017-0362-5","volume":"12","author":"RW Merryman","year":"2017","unstructured":"Merryman RW, Armand P (2017) Immune checkpoint blockade and hematopoietic stem cell transplant. Curr Hematol Malignancy Rep 12(1):44\u201350","journal-title":"Curr Hematol Malignancy Rep"},{"issue":"14","key":"3900_CR57","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","volume":"35","author":"J Bauml","year":"2017","unstructured":"Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A (2017) Pembrolizumab for platinum-and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol 35(14):1542","journal-title":"J Clin Oncol"},{"issue":"11","key":"3900_CR58","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","volume":"17","author":"C Langer","year":"2016","unstructured":"Langer C, Gadgeel S, Borghaei H, Papadimitrakopoulou V, Patnaik A, Powell S, Gentzler R, Martins R, Stevenson J, Jalal S (2016) KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 17(11):1497\u20131508","journal-title":"Lancet Oncol"},{"key":"3900_CR59","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.lungcan.2017.07.034","volume":"112","author":"G Schvartsman","year":"2017","unstructured":"Schvartsman G, Peng SA, Bis G, Lee JJ, Benveniste MF, Zhang J, Roarty EB, Lacerda L, Swisher S, Heymach JV (2017) Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer 112:90\u201395","journal-title":"Lung Cancer"},{"key":"3900_CR60","doi-asserted-by":"publisher","unstructured":"Yan Y, Kumar AB, Finnes H, Markovic SN, Park S, Dronca RS, Dong H (2018) Combining immune checkpoint inhibitors with conventional cancer therapy. Front Immunol 9:1739. https:\/\/doi.org\/10.3389\/fimmu.2018.01739","DOI":"10.3389\/fimmu.2018.01739"},{"key":"3900_CR61","doi-asserted-by":"publisher","unstructured":"Yan Y, Cao S, Liu X, Harrington SM, Bindeman WE, Adjei AA, Jang JS, Jen J, Li Y, Chanana P (2018) CX3CR1 identifies PD-1 therapy\u2013responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI Insight 3(8). https:\/\/doi.org\/10.1172\/jci.insight.97828","DOI":"10.1172\/jci.insight.97828"},{"issue":"7","key":"3900_CR62","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00262-015-1771-8","volume":"65","author":"A Derer","year":"2016","unstructured":"Derer A, Frey B, Fietkau R, Gaipl US (2016) Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors. Cancer Immunol Immunother 65(7):779\u2013786","journal-title":"Cancer Immunol Immunother"},{"issue":"7547","key":"3900_CR63","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM (2015) Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520(7547):373\u2013377","journal-title":"Nature"},{"issue":"2","key":"3900_CR64","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bbmt.2005.09.009","volume":"12","author":"I Alvarez","year":"2006","unstructured":"Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M, Garc\u00eda-Conde J, Sanz G, Arranz R, Bernal MT (2006) Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant 12(2):172\u2013183","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"3900_CR65","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3324\/haematol.11828","volume":"93","author":"P Anderlini","year":"2008","unstructured":"Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, Hosing C, Khouri IF, Couriel D, De Lima M (2008) Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin\u2019s lymphoma: the updated MD Anderson Cancer Center experience. Haematologica 93(2):257\u2013264","journal-title":"Haematologica"},{"issue":"7","key":"3900_CR66","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00277-010-1146-3","volume":"90","author":"R Chen","year":"2011","unstructured":"Chen R, Palmer JM, Popplewell L, Shen J, Smith E, Delioukina M, Kogut N, Rosenthal J, Forman S, Nademanee A (2011) Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma. Ann Hematol 90(7):803\u2013808","journal-title":"Ann Hematol"},{"issue":"10","key":"3900_CR67","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/bmt.2016.115","volume":"51","author":"J Gayoso","year":"2016","unstructured":"Gayoso J, Balsalobre P, Pascual M, Castilla-Llorente C, L\u00f3pez-Corral L, Kwon M, Serrano D, Pi\u00f1ana J, Herrera P, Ferr\u00e1 C (2016) Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed\/refractory Hodgkin lymphoma: Spanish multicenter experience. Bone Marrow Transplant 51(10):1307\u20131312","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"3900_CR68","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/bmt.2013.166","volume":"49","author":"A Raiola","year":"2014","unstructured":"Raiola A, Dominietto A, Varaldo R, Ghiso A, Galaverna F, Bramanti S, Todisco E, Sarina B, Giordano L, Ibatici A (2014) Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin\u2019s lymphoma. Bone Marrow Transplant 49(2):190\u2013194","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"3900_CR69","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J (2016) Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17(9):1283\u20131294","journal-title":"Lancet Oncol"},{"issue":"25","key":"3900_CR70","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","volume":"113","author":"A Di Stasi","year":"2009","unstructured":"Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, Heslop HE, Brenner MK, Dotti G, Savoldo B (2009) T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113(25):6392\u20136402","journal-title":"Blood"},{"issue":"5","key":"3900_CR71","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","volume":"23","author":"C-M Wang","year":"2017","unstructured":"Wang C-M, Wu Z-Q, Wang Y, Guo Y-L, Dai H-R, Wang X-H, Li X, Zhang Y-J, Zhang W-Y, Chen M-X (2017) Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial. Clin Cancer Res 23(5):1156\u20131166","journal-title":"Clin Cancer Res"},{"key":"3900_CR72","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0140-6736(15)00590-5","volume":"386","author":"C-M Wang","year":"2015","unstructured":"Wang C-M, Wu Z-Q, Wang Y, Guo Y-L, Wang X-H, Li X, Dai H-R, Zhang Y-J, Zhang W-Y, Chen M-X (2015) Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin's lymphoma: an open-label phase 1 trial. Lancet 386:S12","journal-title":"Lancet"},{"issue":"9","key":"3900_CR73","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1172\/jci94306","volume":"127","author":"CA Ramos","year":"2017","unstructured":"Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, Bilgi M, Wu MF, Liu H, Grilley B, Bollard CM, Chang BH, Rooney CM, Brenner MK, Heslop HE, Dotti G, Savoldo B (2017) Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest 127(9):3462\u20133471. https:\/\/doi.org\/10.1172\/jci94306","journal-title":"J Clin Invest"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03900-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03900-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03900-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:28:18Z","timestamp":1609460898000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03900-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,2]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["3900"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03900-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,2]]},"assertion":[{"value":"4 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}